All In Biotech

NDA 215430 · Axsome

Auvelity

Bupropion Hydrochloride, Dextromethorphan Hydrobromide · Oral

Breakthrough therapyPriority review

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 18, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

440

96 Phase 3, 24 recruiting

FAERS reports

3,564

841 serious, 36 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . AUVELITY is not approved for use in pediatric patients [see Use in Specific Populations (8.4)] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. AUVELITY is not approved for use in pediatric patients. ( 5.1 , 8.4 )

What it is approved for

From the label in effect Aug 17, 2026.

AUVELITY is a combination of dextromethorphan, an uncompetitive N -methyl D -aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults ( 1.1 ) the treatment of agitation associated with dementia due to Alzheimer’s disease ( 1.2 ) Limitations of Use: AUVELITY is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease (1.2). 1.1 Major Depressive Disorder AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults. 1.2 Agitation Associated with Dementia Due to Alzheimer’s Disease AUVELITY is indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease. Limitations of Use: AUVELITY is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease [see Clinical Studies Section 14.2 ].

Mechanism: Dextromethorphan is an uncompetitive antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist. The mechanism of dextromethorphan in the treatment of MDD and agitation associated with dementia due to Alzheimer’s disease is unclear. Bupropion increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan. The mechanism of action of bupropion in the treatment of MDD is unclear; however, it may be related to noradrenergic and/or dopaminergic mechanisms....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2026 Supplement 18 · Efficacy · priority review Breakthrough therapyLabelMedication GuideLetter
  • Aug 18, 2022 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination · priority review Breakthrough therapyLetterLabelReview
2 products under this application
  • AUVELITY · BUPROPION HYDROCHLORIDE 105MG; DEXTROMETHORPHAN HYDROBROMIDE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • AUVELITY · BUPROPION HYDROCHLORIDE 105MG; DEXTROMETHORPHAN HYDROBROMIDE 45MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupropion" as an intervention, any sponsor and status, largest first.

All 440 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness328
  • feeling abnormal286
  • drug ineffective230
  • anxiety228
  • inappropriate schedule of product administration185
  • nausea179
  • fatigue177
  • depression175
  • off label use175
  • headache155
  • therapy interrupted154
  • tremor130

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20203
20212
202217
2023687
2024944
20251,091
2026820

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Auvelity (Dextromethorphan HBr/Bupropion)

2024 spending

$77.1M

Beneficiaries

16,448

73,075 claims

Per beneficiary

$4,686

$18.58 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,002,001
2023$34,396,888
2024$77,071,790

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,202 on PubMed

Sponsor: Axsome

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.